09:28:17 EDT Fri 29 Mar 2024
Enter Symbol
or Name
USA
CA



Amarantus BioScience Holdings, Inc. – "Eltoprazine, LymPro and MANF: The Path Forward to Value Creation"

2014-10-27 08:23 ET - News Release

New York, NY / October 27, 2014 / Amarantus BioScience Holdings, Inc. (OTCBB: AMBS) today published a new blog post on The Chairman’s Blog, written by the Company’s CEO, Gerald Commissiong. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
"Months of effort are beginning to bear fruit, as [Amarantus has] begun to reach milestones in all three of our key programs," blogged Mr. Commissiong. He highlighted the current status and growth opportunity of each of the Company’s programs, Eltoprazine, LymPro and MANF. Read about Amatantus’ diversified pipeline in Mr. Gerald Commissiong’s blog on TheChairmansBlog.com (http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/eltoprazine-lympro-manf-path-forward-value-creation/).
About Amarantus BioScience Holdings, Inc.
Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.
About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: The Chairmans Blog

© 2024 Canjex Publishing Ltd. All rights reserved.